Retina Clinical Trials in Shanghai, Shanghai Municipality
7 recruitingShanghai, Shanghai Municipality, China
Showing 1–7 of 7 trials
Recruiting
Not Applicable
Functional IOL Implantation in Patients With Epiretinal Membrane
Epiretinal MembraneCataractIntraocular Lens Complication
Eye & ENT Hospital of Fudan University90 enrolled2 locationsNCT06719739
Recruiting
Real World Evidence in China: Faricimab Use in Diabetic Macular Edema, Retinal Vein Occlusion, and Neovascular Age-Related Macular Degeneration (The Farseeing Study)
Neovascular Age-related Macular DegenerationDiabetic Macular EdemaRetinal Vein Occlusion
Hoffmann-La Roche1,000 enrolled41 locationsNCT06439576
Recruiting
Phase 1Phase 2
Safety and Preliminary Efficacy of VG801 in Patients With ABCA4 Mutation-associated Retinal Dystrophy (Stargardt Disease)
Retinal Dystrophy Due to Biallelic ABCA4 MutationsStargardt Disease 1
VeonGen Therapeutics GmbH15 enrolled1 locationNCT07002398
Recruiting
Not Applicable
hAM for Inferior RRD
rhegmatogenous retinal detachment
Eye & ENT Hospital of Fudan University50 enrolled1 locationNCT07081945
Recruiting
Phase 3
Efficacy and Safety of ZVS101e in Patients With Bietti 's Crystalline Dystrophy
Bietti Crystalline Corneoretinal DystrophyBietti Crystalline Dystrophy
Chigenovo Co., Ltd62 enrolled8 locationsNCT06743646
Recruiting
Not Applicable
Minimum Power and Frequency of Repeated Low-level Red-light to Effectively Control Myopia Progression
MyopiaChoroidal thicknessRefractive Error - Myopia+1 more
Shanghai Eye Disease Prevention and Treatment Center108 enrolled1 locationNCT06717048
Recruiting
Phase 1Phase 2
Safety and Efficacy Trial of HG004 for Leber Congenital Amaurosis Related to Rpe65 Gene Mutations (STAR)
Leber Congenital AmaurosisInherited Retinal Diseases Caused by RPE65 Mutations
HuidaGene Therapeutics Co., Ltd.20 enrolled3 locationsNCT05906953